Intended for US healthcare professionals only.
Menu
Visit Patient Site

Novocure® helps you to support your patients using Optune

Patient education materials to assist your patients

There are numerous materials available to help your patients, from learning about Optune during treatment planning, to understanding all the support services available to them through nCompass® support.

Remind your patients to sign up for the Optune Buddy Program

  • Connects prospective and current Optune users and caregivers with experienced users and caregivers based on topics of interest
  • Connections are usually scheduled within 48 hours of a request made via the website or toll-free registration number
Your patients can register online or call the toll-free registration number at 1-844-247-1636 to learn more

Click the orange bars to see patient education resources available for each step of planning and treatment

Diagnosis & treatment planning

The best time to start discussing Optune with your patients is at diagnosis, when creating their individualized treatment plan.

Optune Patient Brochure

Provides a high-level overview of Optune, including clinical efficacy, how to obtain and properly use Optune, and the nCompass Support Program.

View this PDF

Patient MOA video

Patient-friendly presentation of the mechanism of action of Optune, including how Tumor Treating Fields (TTFields) affect GBM tumor cells.

View video

Support Offerings Brochure

Explains the peer-to-peer patient program that connects Optune users and patients/caregivers who are considering, are about to start, or have recently started Optune.

View this PDF

Treatment considerations

nCompass supports your patients at each step of their journey, with materials tailored to their individual needs.

nCompass Patient Brochure

An in-depth look at nCompass from the first Welcome Call to ongoing support and education throughout treatment.

View this PDF

Monthly usage & self-management

A Device Support Specialist (DSS) will provide patients with tips on how to optimize time on therapy.

MyLink™ makes usage data collection easier

  • MyLink lets your patients easily upload their Optune device data to the remote storage server from the comfort of their homes
  • Increases Novocure’s virtual patient support capability and enables your Novocure DSS to better support your patients
  • Gets you the usage information you need to monitor their treatment

Mylink Quick Reference Card

Introduces patients to the MyLink hardware and provides a step-by-step guide of how to use it.

View this PDF

Patient Scalp Care Guidelines

Answers your patients’ questions about scalp care and transducer array placement.

View this PDF

Optune Troubleshooting Tips

A guide for patients and caregivers to refer to when the Optune device alarm goes off to easily determine and address the cause.

View this PDF

Patient Travel Support by nCompass Brochure

Answers frequently asked questions about travel and provides checklists of what to pack and bring when traveling with Optune.

View this PDF

Enroll your patients in the Optune Buddy Program today!

The Buddy Program lets them talk to Optune users and caregivers to learn more about living with glioblastoma (GBM) and treatment with Optune

We are pleased to offer the Optune Buddy Program. The program provides helpful information for your patients living with GBM by connecting them with experienced Optune users and caregivers who can share their insights.

In addition, once you complete this enrollment form, we’ll start sharing information and resources to help support your patients as they learn about GBM and treatment options. They will receive:

  • An overview of GBM treatment options
  • Information on the benefits and side effects of Optune
  • Connections to the GBM community and to Optune users
  • Notices about live events in their area and webinars

Please select which applies to you:

GBM, glioblastoma.

Learn more below

Skin AE management

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.

Read more

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.

Leaving Optune.com

Novocure does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.

OK

Sie verlassen nun die Website welche nur für Verbraucher/Patienten der USA vorgesehen ist. Die Website welche Sie nun öffnen richtet sich ausschließlich an in Deutschland ansässige Verbraucher/Patienten.

Bitte klicken Sie auf “Ok” um zu bestätigen dass Sie verstehen, dass sich diese Internet-Seite ausschließlich an Verbraucher/Patienten in Deutschland richtet.

You are currently leaving Optune.com. The site you are about to visit is intended for German users/patients only.

OK

現在アメリカ国内向けの専用のサイトから日本の医療従事者向けの専用サイトへ移動しようとしています。

よろしければ ”OK” をクリックすることで日本の医療従事者向け専用のサイトへ移動します。

You are currently leaving Optune.com. The site you are about to visit is intended for Japanese residents only.

OK